Understanding FGF signaling to treat spinal defects (FANTASIA)

Professor Chan, Danny   (Principal Investigator (PI))

Dr Legeai-Mallet Laurence   (Co-Investigator)

48

2020-03-01

2994529

Understanding FGF signaling to treat spinal defects (FANTASIA)

Achondroplasia, cartilage, intervertebral disc, spine deformity, therapy

Developmental Biology

A_HKU704/19

ANR / RGC Joint Research Scheme

2019

On-going

Spinal defects associated with short statures are genetic skeletal disorders that pose major socio economic burdens. Defects in FGFR3 signalling are common causes of short statures. Impaired growth of long bones due to excessive activation of FGFR3 signalling are well studied, but not for spinal defects such as lordosis, kyphosis, and stenosis. Recently, we have identified defects in the structure of the intervertebral discs and vertebral bodies that relate to abnormal chondrocyte proliferation and differentiation. These data are consistent with our novel findings that chondrocytes from the endplate cartilage contributes to the homeostasis of the intervertebral disc. Deciphering the molecular mechanisms of FGF signaling of skeletal development, growth, and aging is critical for the design of effective therapies for children and adult patients with short stature. The Paris and Hong Kong team has the combined synergistic expertise and resources in realizing the goal of FANTASIA.